A significant drug-metabolizing role for CYP3A5?

Drug Metabolism and Disposition

Volumn 31, Issue 12, 2003, Pages 1526-1531

  Williams, J Andrew ^a   Cook, Jack ^a   Hurst, Susan I ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; MIDAZOLAM;

ALLELE; COMPARATIVE STUDY; DRUG METABOLISM; ENZYME SUBSTRATE; GENOTYPE; HOMOZYGOTE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MICROSOMES, LIVER; MIDAZOLAM; PHARMACEUTICAL PREPARATIONS;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0345707481     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.12.1526     Document Type: Review

References (35)

1. Anttila S, J. Hukkanen, Hakkola J, Stjernvall T, Beaune P, Edwards RJ, Boobis AR, Pelkonen O, and Raunio H (1997) Expression and localization of CYP3A4 and CYP3A5 in human lung. Am J Respir Cell Mol Biol 16:242-249.
2. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin, HV, et al. (1989) Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver, cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem 264: 10388-10395.
3. Balson KR, Morgan DJ, Richmond BH, McAlindon ME, Elliott SL, and Yeomans ND (1996) Pharmacokinetics of midazolam in Vietnamese subjects. J Gastroenterol Hepatol 11:1177-1180.
4. Ekins S, Stresser DM, and Williams JA (2003) In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol Sci. 24:161-166.
5. Gibbs MA, Thummel KE, Shen DD, and Kunze KL (1999) Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 27:180-187.
6. Gillam EM, Wunsch RM, Ueng YF, Shimada T, Reilly PE, Kamataki T, and Guengerich FP (1997) Expression of cytochrome P450 3A7 in Escherichia coli: effects of 5′ modification and catalytic characterization of recombinant enzyme expressed in bicistronic format with NADPH-cytochrome P450 reductase. Arch Biochem Biophys 346:81-90.
7. Goh B-C, Lee S-C, Wang L-Z, Fan L, Guo J-Y, Lamba J, Schuetz E, Lim R, Lim H-L, Ong A-B, and Lee H-S (2002). Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 20:3683-3690.
8. Gorski JC, Hall SD, Jones DR, VandenBranden M, and Wrighton SA (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:1643-1653.
9. Goto M, Masuda S, Saito H, Uemoto S, Kiuchi T, Tanaka K, and Inui K (2002) C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 12:451-457.
10. Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK, Watkins PB, and Hall SD (1996) Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 50:52-59.
11. Heizmann P, Eckert M, and Ziegler WH (1983). Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol 16 (Suppl 1):43S-49S
12. Hirota N, Ito K, Iwatsubo T, Green CE, Tyson CA, Shimada N, Suzuki H, and Sugiyama Y (2001) In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans, Biopharm Drug Dispos 22:53-71.
13. Hukkanen J, Vaisanen T, Lassila A, Piipari R, Anttila S, Pelkonen O, Raunio H, and Hakkola J (2003) Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J Pharmacol Exp Ther 304:745-752.
14. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, et al. (1999) Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res (NY) 16:408-414.
15. Kliewer SA, Goodwin B, and Wilson TM (2002) The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 23:687-702.
16. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, Nuessler A, Neuhaus P, Eichelbaum M, Zanger U, and Wojnowski L (2002) Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30:1108-1114.
17. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM, and Watkins PB (1994) CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247-259.
18. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
19. Landes N, Pfluger P, Kluth D, Birringer M, Ruhl R, Bol GF, Glatt H, and Brigelius-Flohe R (2003) Vitamin E activates gene expression via the pregnane X receptor. Biochem Pharmacol 65:269-273.
20. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, and Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162-172.
21. Macphee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, Goldberg L, and Holt DW (2002) Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74: 1486-1489.
22. Maenpaa J, Hall SD, Ring BJ, Strom SC, and Wrighton SA (1998) Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone. Pharmacogenetics 8:137-155.
23. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, and Thummel KE (1996) First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60:14-24.
24. Shih PS and Huang JD (2002) Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes, Drug Metab Dispos 30:1491-1496.
25. Smith MT, Eadie MJ, and Brophy TO (1981) The pharmacokinetics of midazolam in man. Eur J Clin Pharmacol 19:271-2781.
26. Tateishi T, Watanabe M, Moriya H, Yamaguchi M, Sato T, and Kobayashi S (1999) No ethnic differences between Caucasian and Japanese samples in the expression frequency of CYP3A5 and CYP3A7 proteins. Biochem Pharmacol 57:935-939.
27. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, and Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491-502.
28. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, McVicar JP, Barr, DM, et al. (1994) Use of midazolam as a human cytochrome P450 3A probe. I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 271:549-556.
29. Westlind-Johnsson A, Malmebo S, Johanssen A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, and Ingelman-Sundberg M (2003) Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31:755-761.
30. Williams JA and Phillips DH (2000) Mammary expression of xenobiotic metabolizing enzymes and their potential role in breast cancer. Cancer Res 60:4667-4677.
31. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, and Wrighton SA (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5 and CYP3A7. Drug Metab Dispos 30:883-891.
32. Wrighton SA, Brian WR, Sari M-A, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, and Vandenbranden M (1990) Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 38:207-213.
33. Wrighton SA, Ring BJ, Watkins PB, and Vandenbranden M (1989) Identification of a polymorphically expressed member of the human cytochrome P450III family. Mol Pharmacol 36:97-105.
34. Yates CR, Zhang W, Song P, Gaber AO, Honaker MR, Kotb M, Alloway RR, and Meibohm B (2002) Effect of CYP3A5 genotype on cyclosporine disposition: a pilot study. Clin Pharmacol Ther 71:P2.
35. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, Boyle G, Law Y, Miller S, Lamba J, and Burckart GJ (2003) Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 3:477-483.